From bad to worse: Comorbidity severity and quality of life after treatment for early-stage prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 4, 2010, Pages 320-327

  Daskivich, T J ^a   Van De Poll Franse, L V ^b   Kwan, L ^a   Sadetsky, N ^c   Stein, D M ^d   Litwin, M S ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b The Netherlands   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

comorbidity; outcome assessment; prostate; prostatic neoplasms; quality of life

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER FUNCTION; CANCER STAGING; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; QUESTIONNAIRE; SEXUAL FUNCTION; TOTAL ILLNESS BURDEN INDEX FOR PROSTATE CANCER;

AGED; CARCINOMA; COMORBIDITY; DISEASE PROGRESSION; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TIME FACTORS; URINATION DISORDERS;

EID: 78649333817     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.33     Document Type: Article

References (19)

1. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626-631.
2. Fowler JE Jr TF, Renfroe DL. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol 1996; 156: 1714-1718.
3. Tewari A JC, Divine G, Crawford ED, Gamito EJ, Demers R, Menon M. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004; 171: 1513-1519.
4. Arredondo SA, Elkin EP, Marr PL, Latini DM, DuChane J, Litwin MS et al. Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: data from CaPSURE. Urology 2006; 67: 559-565.
5. Hu JC, Elkin EP, Pasta DJ, Lubeck DP, Kattan MW, Carroll PR et al. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol 2004; 171: 703-707.
6. van de Poll-Franse LV, Sadetsky N, Kwan L, Litwin MS. Severity of cardiovascular disease and health-related quality of life in men with prostate cancer: a longitudinal analysis from CaPSURE. Qual Life Res 2008; 17: 845-855.
7. Albertsen PC FD, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996; 156: 127-132.
8. Stier DM, Greenfield S, Lubeck DP, Dukes KA, Flanders SC, Henning JM et al. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology 1999; 54: 424-429.
9. Litwin MS, Greenfield S, Elkin EP, Lubeck DP, Broering JM, Kaplan SH. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer 2007; 109: 1777-1783.
10. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry. J Urol 2004; 171: 1393-1401.
11. Lubeck DP, Litwin MS, Henning JM, Stier DM, Mazonson P, Fisk R et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1996; 48: 773-777.
12. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
13. Greenfield S, Sullivan L, Dukes KA, Silliman R, D'Agostino R, Kaplan SH. Development and testing of a new measure of case mix for use in office practice. Med Care 1995; 33: AS47-AS55.
14. Stewart AL, Hays RD, Ware Jr JE. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988; 26: 724-735.
15. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998; 36: 1002-1012.
16. Ware Jr JE, Kosinski M, Keller SK. SF-36 Volume: Physical and Mental Health Summary Scales: A Users Manual. The Health Institute New England Medical Center: Boston, MA, 1994.
17. Talcott JA, Manola J, Clark JA, Kaplan I, Beard CJ, Mitchell SP et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 2003; 21: 3979-3986.
18. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283: 354-360.
19. Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst 2009; 101: 888-892.